Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Malley

Showing results (71-80 of 124) with videos related to

Pageof 13
Sort By:
Plos Pathogens|June 13, 2009
Pneumococcal capsular polysaccharide structure predicts serotype prevalenceDaniel M Weinberger, Krzysztof Trzciński, Ying-Jie Lu, et al.
Cell Host & Microbe|February 16, 2011
T(H)17-based vaccine design for prevention of Streptococcus pneumoniae colonizationKristin L Moffitt, Todd M Gierahn, Ying-jie Lu, et al.
Molecular Biotechnology|June 24, 2021
Optimization of Expression and Purification of Schistosoma mansoni Antigens in Fusion with RhizavidinMayra M F Barbosa, Alex I Kanno, Violeta Pancakova, et al.
The Pediatric Infectious Disease Journal|January 3, 2020
A Phase 1 Randomized, Placebo-controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of Inactivated Streptococcus pneumoniae Whole-cell Vaccine in AdultsCheryl A Keech, Royce Morrison, Porter Anderson, et al.
Vaccine|June 11, 2022
Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 yearsGurunadh R Chichili, Ronald Smulders, Vicki Santos, et al.
Vaccine|June 19, 2024
Corrigendum to "Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years" [Vaccine 40 (2022) 4190-4198]Gurunadh R Chichili, Ronald Smulders, Vicki Santos, et al.
Vaccine|February 6, 2017
IL-17A and complement contribute to killing of pneumococci following immunization with a pneumococcal whole cell vaccineIvana B Campos, Muriel Herd, Kristin L Moffitt, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 21, 2008
Does pneumococcal conjugate vaccine influence Staphylococcus aureus carriage in children?Gili Regev-Yochay, Debby Bogaert, Richard Malley, et al.
Infection and Immunity|March 12, 2014
Toll-like receptor 2-dependent protection against pneumococcal carriage by immunization with lipidated pneumococcal proteinsKristin Moffitt, Mojca Skoberne, Angela Howard, et al.
Vaccine|February 15, 2024
Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: A phase 1 randomized controlled trialDorota Borys, Richard Rupp, Ronald Smulders, et al.
Pageof 13

Showing results (71-80 of 124) with videos related to

Sort By:
Pageof 13
Plos Pathogens|June 13, 2009
Pneumococcal capsular polysaccharide structure predicts serotype prevalenceDaniel M Weinberger, Krzysztof Trzciński, Ying-Jie Lu, et al.
Cell Host & Microbe|February 16, 2011
T(H)17-based vaccine design for prevention of Streptococcus pneumoniae colonizationKristin L Moffitt, Todd M Gierahn, Ying-jie Lu, et al.
Molecular Biotechnology|June 24, 2021
Optimization of Expression and Purification of Schistosoma mansoni Antigens in Fusion with RhizavidinMayra M F Barbosa, Alex I Kanno, Violeta Pancakova, et al.
The Pediatric Infectious Disease Journal|January 3, 2020
A Phase 1 Randomized, Placebo-controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of Inactivated Streptococcus pneumoniae Whole-cell Vaccine in AdultsCheryl A Keech, Royce Morrison, Porter Anderson, et al.
Vaccine|June 11, 2022
Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 yearsGurunadh R Chichili, Ronald Smulders, Vicki Santos, et al.
Vaccine|June 19, 2024
Corrigendum to "Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years" [Vaccine 40 (2022) 4190-4198]Gurunadh R Chichili, Ronald Smulders, Vicki Santos, et al.
Vaccine|February 6, 2017
IL-17A and complement contribute to killing of pneumococci following immunization with a pneumococcal whole cell vaccineIvana B Campos, Muriel Herd, Kristin L Moffitt, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 21, 2008
Does pneumococcal conjugate vaccine influence Staphylococcus aureus carriage in children?Gili Regev-Yochay, Debby Bogaert, Richard Malley, et al.
Infection and Immunity|March 12, 2014
Toll-like receptor 2-dependent protection against pneumococcal carriage by immunization with lipidated pneumococcal proteinsKristin Moffitt, Mojca Skoberne, Angela Howard, et al.
Vaccine|February 15, 2024
Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: A phase 1 randomized controlled trialDorota Borys, Richard Rupp, Ronald Smulders, et al.
Pageof 13